Business Wire

MAVENIR

Share
Mavenir and Qualcomm to Accelerate 5G High-Density Open vRAN Deployments

Mavenir, the cloud-native network infrastructure provider building the future of networks, and Qualcomm Technologies, Inc., a leader enabling intelligent computing everywhere, today announce the latest developments in the technology leaders’ strategic collaboration to deliver energy-efficient solutions for high-density cell site configurations that will drive enhanced 5G coverage and capacity in urban areas. The ongoing collaboration is leveraging the Qualcomm® X100 5G RAN Accelerator Card and Mavenir’s Open virtualised Radio Access Network (Open vRAN) solution to accelerate operator deployment of cloud-native, virtualised Open 5G networks – designed to enable enhanced scalability, sustainability, capacity, and efficiency.

Mavenir and Qualcomm Technologies’ solution optimises Total Cost of Ownership (TCO) for operators by substantially reducing CPU/core usage and energy consumption requirements through improved power efficiency. This delivers an ideal solution for delivery at scale, including Fixed Wireless Access (FWA) deployments where an extensive network rollout is required to provide robust coverage and connectivity. Moreover, the joint solution offers more fronthaul port capacity.

The collaboration has already successfully demonstrated the integration of in-line acceleration, with the Qualcomm X100 5G RAN accelerator card and Mavenir’s cloud-native virtualised Distributed Unit (vDU) software solution in a live massive MIMO use case, achieving a capacity of 3Gbps in a multi-user environment.

The Qualcomm X100 5G RAN acceleration card is a PCIe-based solution that offloads compute-intensive tasks from the CPU to the card, designed to enhance the performance and capacity of vRAN deployments. The solution integrates through a standards-based FAPI interface, enabling more seamless interoperability and compatibility.

BG Kumar, President, Access Networks, Platforms and Digital Enablement at Mavenir, said: “Mavenir is excited to grow its collaboration with Qualcomm Technologies to accelerate the adoption of open and disaggregated vRAN architectures and innovate high-density solutions for 5G networks. Combining the strengths of Mavenir's Open vRAN solution with Qualcomm Technologies-powered in-line acceleration with Qualcomm X100 5G RAN accelerator card allows operators to benefit from a sustainable 5G RAN infrastructure and deploy 5G networks with unprecedented flexibility, scalability, and cost efficiency.”

“As a global technology leader in 5G, Qualcomm Technologies is pleased to collaborate with Mavenir to further the enablement and adoption of open and virtualised RAN,” said Gerardo Giaretta, Vice President, Product Management, Qualcomm Technologies, Inc. “Harnessing inline acceleration with the Qualcomm X100 5G RAN Accelerator Card, together with Mavenir’s cloud-native vDU solution, we are evolving performance, efficiency and scalability for modern networks.”

Notes to editors:

About Mavenir

Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com

Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)

To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).

Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.

Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221727374/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye